# AeroRx Therapeu&cs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerorx-therapeu-cs

- Industry: Biotechnology
- Headquarters: La Jolla, US
- Website: www.aerorxtx.com
- Total disclosed funding: $10M
- Latest round: Series A (Sep 25, 2025)
- Investors on record: 3

## About

AeroRx Therapeutics, Inc. is a US-based biopharmaceutical company focused on developing advanced nebulized therapies for chronic obstructive pulmonary disease (COPD), targeting patients with specific treatment needs.AeroRx Therapeutics, Inc. specializes in developing innovative nebulized therapies. Founded in 2023 and headquartered in La Jolla, US, the company has undergone strategic developments to enhance its product offerings. In 2025, AeroRx completed its first funding round, raising USD 21.000 mn in Series A funding, led by Avalon Bio Ventures, with participation from Alexandria Venture Investments and Correlation Ventures. The total amount raised now stands at USD 21.000 mn.AeroRx Therapeutics focuses on developing advanced nebulized combination therapies targeting patients with chronic obstructive pulmonary disease (COPD). The company offers AERO-007, a fixed-dose combination of long-acting beta2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), and AERO-111, a triple combination product featuring an inhaled corticosteroid (ICS). These therapies aim to enhance efficacy and improve compliance among COPD patients in the US, where over 16 million individuals are affected by this disease. AeroRx is actively engaged in late-stage clinical development to address significant treatment gaps in COPD management.AeroRx Therapeutics has structured its business model around the development and commercialization of its nebulized therapies, focusing on partnerships within the healthcare sector. The company intends to generate revenue through direct sales to healthcare providers and institutions, alongside agreements with pharmaceutical distributors and wholesalers. The flagship product, AERO-007, is positioned to establish a presence in both hospital and outpatient settings, with transaction structures based on bulk procurement agreements and potential reimbursement strategies from insurance providers.In October 2025, AeroRx Therapeutics, Inc. raised USD 21.000 mn in Series A funding, led by Avalon Bio Ventures. This funding will support further testing of its lead treatment and preparation for regulatory approval. The company is focused on launching new products and expanding into new markets, particularly targeting additional geographical regions where COPD prevalence is high. The strategic use of recent funding will be crucial in advancing their product development and market entry efforts.

## Funding rounds

- Series A, Sep 25, 2025, $10M — Alexandria Venture Investments, Correlation Ventures, Avalon Bio Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series A
- Avalon Bio Ventures (https://capitalatlas.ai/funds/avalon-bio-ventures) — Series A